|Mr. Ralph H. Thurman||Independent Exec. Chairman||N/A||N/A||1949|
|Mr. Lawrence A. Kenyon||CFO, Treasurer, Company Sec. & Director||562.88k||N/A||1966|
|Mr. Terry Dagnon||Chief Operating Officer||159.68k||N/A||1962|
|Mr. Jeffrey Evanson||Chief Commercial Officer||159.68k||N/A||1969|
|Mr. C. Russell Trenary III||Pres, CEO & Director||N/A||N/A||1958|
|Rick Gregory||Director of Marketing & Communications||N/A||N/A||N/A|
|Dr. Balu N. Balasubramanian||Advisor||N/A||N/A||N/A|
|Ms. Elizabeth A. Yamashita||Advisor||N/A||N/A||1961|
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.
Outlook Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.